Claims for Patent: 4,558,034

Summary for Patent: 4,558,034

Title:	Inhibitors of bacterial collagenase
Abstract:	This invention relates to amino acid derivatives that are useful as inhibitors of bacterial collagenase. The compounds of this invention have a general formula: ##STR1## wherein R is alkyl, aralkyl, aryl, alkoxy, aryloxy, hydroxy or pharmaceutically acceptable salts thereof; R.sub.1 is hydrogen, alkali metal, lower alkyl, phenyl lower alkyl, or phenyl, or substituted phenyl wherein the substituent is halo, lower alkoxy or lower alkyl or nitro or carboxy or cyano, and pharmaceutically acceptable salts thereof; R.sub.2, R.sub.3 and R.sub.4 is hydrogen or alkyl; R.sub.2 and R.sub.4 may be the side groups found on the 20 common .alpha.-amino acids; R.sub.3 and R.sub.4 may be connected together to form an alkylene bridge of from 2 to 4 carbon atoms; Y is alkoxy, aryloxy, primary amide, amino acid derivative or ##STR2## where R.sub.5 and R.sub.6 is hydrogen or alkyl; R.sub.5 and R.sub.6 may be connected together to form an alkylene bridge of from 2 to 4 carbon atoms; X is hydroxyl or pharmaceutically acceptable salts thereof, or an amino acid derivative.
Inventor(s):	Galardy; Richard E. (Lexington, KY), Grobelny; Damian (Lexington, KY)
Assignee:	The Board of Trustees of the University of Kentucky (Lexington, KY)
Application Number:	06/576,005
Patent Claims:	1. A method for inhibiting bacterial collagenase in vivo wherein the bacteria are selected from the group consisting of Clostridium and Pseudomonas, which comprises administering to a human being a collagenase inhibiting effective amount of a pharmaceutical composition including a compound of the formula: ##STR12## wherein R is alkyl, aralkyl, aryl, alkoxy, aryloxy, hydroxy or pharamceutically acceptable salts thereof; R.sub.1 is hydrogen, alkali metal, lower alkyl, phenyl lower alkyl, or phenyl, or substituted phenyl wherein the substituent is halo, lower alkoxy or lower alkyl or nitro or carboxy or cyano, and pharmaceutically acceptable salts thereof; R.sub.2, R.sub.3 and R.sub.4 are hydrogen or alkyl; R.sub.2 and R.sub.4 are selected from the group consisting of straight and branched chain alkyl, hydroxy alkyl, carboxy alkyl, aralkyl, amino alkyl, carboxamide alkyl, mercapto alkyl, phenyl alkyl, hydroxy phenyl alkyl, guanidino alkyl, imidazoyl alkyl, indolyl alkyl, and pyrrolidinyl; R.sub.3 and R.sub.4 may be connected together to form an alkylene bridge of from 2 to 4 carbon atoms; Y is alkoxy, aryloxy, primary amide, alanine benzyl ester or ##STR13## where R.sub.5 and R.sub.6 is hydrogen or alkyl; R.sub.5 and R.sub.6 may be connected together to form an alkylene bridge of from 2 to 4 carbon atoms; and X is hydroxyl or pharmaceutically acceptable salts thereof, in admixture with a pharmaceutically acceptable carrier. 2. A method according to claim 1, wherein the composition is adapted for oral ingestion and is administered orally. 3. A method according to claim 1, wherein the composition is adapted for parenteral administration and is administered parenterally. 4. A method according to claim 1, in the form of a tablet or capsule. 5. A method according to claim 1, in the form of an aqueous solution. 6. A method of inhibiting the action of a bacterial collagenase in vitro wherein the bacteria are selected from the group consisting of clostridium and Pseudomonas, by allowing the collagenase to react with an inhibition-effective amount of a compound of the formula: ##STR14## wherein R is alkyl, aralkyl, aryl, alkoxy, aryloxy, hydroxy or pharmaceutically acceptable salts thereof; R.sub.1 is hydrogen, alkali metal, lower alkyl, phenyl lower alkyl, or phenyl, or substituted phenyl wherein the substituent is halo, lower alkoxy or lower alkyl or nitro or carboxy or cyano, and pharmaceutically acceptable salts thereof; R.sub.2, R.sub.3 and R.sub.4 are hydrogen or alkyl; R.sub.2 and R.sub.4 are selected from the group consisting of straight and branched chain alkyl, hydroxy alkyl, carboxy alkyl, aralkyl, amino alkyl, carboxamide alkyl, mercapto alkyl, phenyl alkyl, hydroxy phenyl alkyl, guanidino alkyl, imidazoyl alkyl, indolyl alkyl, and pyrrolidinyl; R.sub.3 and R.sub.4 may be connected together to form an alkylene bridge of from 2 to 4 carbon atoms; Y is alkoxy, aryloxy, primary amide, alanine benzyl ester or ##STR15## where R.sub.5 and R.sub.6 is hydrogen or alkyl; R.sub.5 and R.sub.6 may be connected together to form an alkylene bridge of from 2 to 4 carbon atoms; and X is hydroxyl or pharmaceutically acceptable salts thereof, in admixture with a pharmaceutically acceptable carrier in an appropriate solution. 7. The method of claim 6, wherein R=ethyl, R.sub.1 =K.sup.+ or H, R.sub.2 =isoamyl, R.sub.3 =H, R.sub.4 =benzyl, and Y=NH.sub.2. 8. The method of claim 1, wherein R=isoamyl, R.sub.1 =K.sup.+ or H, R.sub.2 =H, R.sub.3 +R.sub.4 =--CH.sub.2 CH.sub.2 CH.sub.2 --, and Y=Alanine. 9. The method of claim 1, wherein R=ethyl, R.sub.1 =K.sup.+ or H, R.sub.2 =H, R.sub.3 +R.sub.4 =--CH.sub.2 CH.sub.2 CH.sub.2 --, and Y=Alanine. 10. The method of claim 1, wherein R=isoamyl, R.sub.1 =benzyl, R.sub.2 =H, R.sub.3 +R.sub.4 =--CH.sub.2 CH.sub.2 CH.sub.2 --, and Y=Alanine benzyl ester. 11. The method of claim 1, wherein R=ethyl, R.sub.1 =benzyl, R.sub.2 =H, R.sub.3 +R.sub.4 =--CH.sub.2 CH.sub.2 CH.sub.2 -, and Y=Alanine benzyl ester.

Details for Patent 4,558,034

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-03-29